Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213364 | 0.89 | NAMPT (0.36) | BRD4CCKBRCYP1A2CYP2D6NAMPT | |
| SCHEMBL2211370 | 0.88 | LOXL2 (0.34) | NAMPTMAPTKDM4E | |
| SCHEMBL2215145 | 0.87 | BRD4 (0.36) | BRD4CCKBRNAMPTMAPT | |
| SCHEMBL4376898 | 0.85 | PIP4K2C (0.37) | BRD4NAMPTGRM4MAPTTDP1 | |
| SCHEMBL2212145 | 0.82 | BRD4 (0.39) | BRD4CCKBRMAPT | |
| SCHEMBL2214689 | 0.80 | NAMPT (0.34) | NAMPTMAPTKDM4EMAPK1 | |
| SCHEMBL2215529 | 0.80 | ALDH1A1 (0.38) | MAPTKDM4E | |
| SCHEMBL2213218 | 0.80 | TRPV1 (0.42) | NAMPTMAPTKDM4E | |
| SCHEMBL2215195 | 0.80 | MEN1 (0.45) | MAPTKDM4E | |
| SCHEMBL2213958 | 0.80 | KDM4E (0.37) | NAMPTMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797096-B1 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1797096-A2 | NOVEL PYRAZOLOPYRIMIDINES | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027346-A2 | NOVEL PYRAZOLOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | BRD4 708/4885CCKBR 2961/4885CYP1A2 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.